Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kadcyla Positioned For Wide Use In Metastatic Breast Cancer

Executive Summary

Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line+ mBC, but labeling allows first-line treatment in a subset of patients at high risk.

You may also be interested in...



Genentech Wins Attorneys' Fees After Phigenix's Aggressive Patent Suit

"Tipping point" occurred when Phigenix changed theory that Genentech's Kadcyla infringed its patent; CEO may be on hook for attorneys' fees.

Surprise! Roche Says It Will Not Pursue Herceptin Patents In India

In a surprising move, Roche has decided to give up its patents for Herceptin in India, leaving the way open for generic drug makers eyeing the booming market. But do any local firms have the capabilities to develop and manufacture a biosimilar of trastuzumab?

Roche CEO Severin Schwan Fueled By Innovation, Emerging Markets: An Interview With PharmAsia News

Roche CEO Severin Schwan says the Swiss group’s recent revamps, lack of patent expiries, and ongoing drug innovations give the world’s largest maker of cancer drugs a strong position to expand its sales globally, helped by new cutting-edge therapies and creative business approaches.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel